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 ABSTRACT
The spectrum of neuromuscular diseases encountered in the 
ICUs today has rapidly evolved over the last decades. Mul-
tiple predisposing factors are involved in the development 
of neuromuscular complications in intensive care patients. 
Those complications broadly classified into weakness from 
the preexisting neuromuscular disease exacerbated by criti-
cal illness or the complication of the critical illness itself. Pa-
tients, when unresponsive, confused, or sedated precludes 
careful clinical examination. A careful schematic approach 
that involves acquiring extensive history, any underlying in-
fections, use of any offending medications, and the course 
of presenting illness will help in delineating the underlying 
etiology. Here in this review, we describe many causes and 
the pathophysiology that contribute to the development of 
neuromuscular weakness in the ICU. A comprehensive in-
vestigation protocol must strictly be adhered to all the cases 
in the ICU settings to reduce the mortality and morbidity.  
Keywords: Critical illness polyneuropathy, critical illness 
myopathy, ICU related neuromuscular weakness, myopathy, 
complications of sepsis.
Introduction
Critically ill patients in the ICU get exposed to mul-
tiple risk factors that increase the likelihood of damage to 
the peripheral nervous system. Fluid and electrolyte dis-
turbances, catabolic stressors, nutritional deficiency, and 
medications collectively increase the risk for neuromuscu-
lar damage, thus prolonging hospital stay, delaying recovery 
and increasing morbidity and mortality.1, 2 The most com-
mon causes of neuromuscular weakness in ICU patients 
are critical illness neuropathy and critical illness myopathy, 
which usually presents as failure to wean off from ventilator 
and decreased limb movements.1,2,4,5 The incidence rate for 
acquiring weakness from critical illness neuropathy (CIN) 
and critical illness myopathy (CIM) has drastically in-
creased and is twice as common as primary neuromuscular 
causes such as GBS and motor neuron diseases.3,4 Recently, 
CIM is more commonly encountered than CIP. Early diag-
nosis and prompt treatment are necessary as complications 
such as ventilatory failure and aspiration pneumonia sig-
nificantly increase morbidity and mortality. 
Classification 
Although there are multiple causes for generalized 
weakness in a patient in ICU motor weakness can be broad-
ly classified due to:
1. NEUROMUSCULAR COMPLICATIONS OF 
CRITICAL ILLNESS
2. PRE-EXISTING NEUROMUSCULAR 
DISORDERS 
Motor weakness can further lateralized to the anatomi-
cal site of involvement of a disease process. Table 1 provides 
common causes of ICU associated weakness in neuromus-
cular patients.
1. Neuromuscular Complications of Critical Illness
ICU acquired neuromuscular weakness is a major 
cause of morbidity in critically ill patients.3-4 It significantly 
affects the overall prognosis and increases the length of hos-
pitalization.3-4 The three most common causes of acquired 
neuromuscular weakness in ICU patients are critical illness 
polyneuropathy, critical illness myopathy, and prolonged 
neuromuscular blockade. 
CIP affects between one third and half of the most se-
verely critically ill patient in the intensive care units (ICU).2,5 
A systematic review reported a median prevalence of CIP as 
43% (interquartile range 25–75%) in over 31 studies.3 Criti-
cal illness polyneuropathy and myopathy is seen in approxi-
mately 25–45% of critically ill patients who are admitted to 
intensive care units.5
Both CIP and CIM present as symmetrical, diffuse flac-
cid muscle weakness affecting extremities and respiratory 
muscles with relative sparing of cranial nerves.2-3,5 Multiple 
possible factors play a role in the development of neuromus-
cular weakness in critically ill patients; the major ones are sys-
temic inflammatory response syndrome (SIRS), corticoste-
roid use, and neuromuscular blocking agents.2,5 See Figure 1.
Critical Illness Polyneropathy
CIP usually presents as sensorimotor axon loss poly-
neuropathy, affecting distal muscles more than proximal 
muscles in the early course, later progressing to generalized 
muscle weakness with absent reflexes.2-3,5 It was initially 
described as a rare complication secondary to sepsis and 
multi-organ failure.2,4,6 The majority of the patients have 
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concomitant encephalopathy due to underlying sepsis or 
organ failure.2,7 Hyperglycemia, hypoalbuminemia, and par-
enteral nutrition are also known to exacerbate the develop-
ment of CIP.5,7 Impaired microcirculation due to inflamma-
tory responses leads to decreased nerve perfusion resulting 
in nerve hypoxia.6-7
The earliest clinical suspicion arises when it is difficult 
to wean the patient from a ventilator, and other common 
presentations include tetraplegia and absent deep tendon 
reflexes.4,7 Severity is proportional to the length of ICU 
stay.5,7
The most important diagnostic test is the Electro di-
agnostic study (nerve conduction+ electromyography). 
Nerve conduction velocities may be normal or reduced, but 
the amplitude of sensory responses and motor responses is 
significantly decreased or even absent.3,7 Features of acute 
denervation such as fibrillation, positive sharp waves, and 
reduced recruitment are evident in needle electrode stud-
ies. Motor unit potential has a long duration, high amplitude 
and polyphasic morphology.3 Nerve biopsy shows severe 
axonal degeneration of motor and sensory fibers affecting 
distal segments primarily.3
Treatment usually comprises aggressive management 
of SIRS and supportive measures such as fluid resuscita-
tion, antibiotic therapy, and physical therapy.5 Recovery 
usually occurs over weeks to months.2,5 Long term progno-
Table 1: Causes of generalized weakness in ICU and their anatomical localization
Localization Preexisting Neuromuscular Disorder Complication of Critical illness
Spinal cord Trauma 
Infarction
Transverse myelitis
Unknown
Anterior horn cell ALS
Poliomyelitis
Hopkins syndrome
Peripheral nerve GBS
Chronic inflammatory demyelinating 
polyneuropathy
Critical illness polyneuropathy
Neuromuscular junction Myasthenia gravis
Lambert-Eaton syndrome
Botulism
Prolonged neuromuscular blockade
Muscle Muscular dystrophy
Polymyositis
Metabolic/congenital
Mitochondrial
Critical illness myopathy
                    INFECTIONS, TRAUMA, BURNS, SEPSIS
                                                 ↓
                           INFLAMMATORY   RESPONSE
                                  ↓                                    ↓
                         HUMORAL                       CELLULAR
                         RESPONSE                     RESPONSE
         (IL, TNF, FREE RADICALS)        (NEUTROPHILS, LYMPHOCYTES)
                                                     ⇊
 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
            ↓                    ↓                               ↓
  ORGAN FAILURE    ⟷    STEROID USE    ⟷   NEUROMUSCULAR BLOCKADE
                                                   ⇓
CRITICAL ILLNESS POLYNEUROPATHY / CRITICAL ILLNESS MYOPATHY
Figure 1: Pathogenesis of development of critical illness polyneuropathy/myopathy in ICU
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sis depends upon the severity of the underlying disease pro-
cess and patients with only CIM having a better prognosis 
than those with CIN only or even those with CIN+CIM.5
Critical Illness Myopathy
CIM is the major contributor of ICU related neuro-
muscular weakness.2-3,5 CIM usually develops in patients 
taking prolonged high dose steroids or on neuromuscular 
blocking agents.6,8 It characteristically presents as diffuse 
weakness affecting both limbs, affecting distal muscles and 
proximal muscle groups. Facial muscle and sometimes ocu-
lar muscle involvement can be seen.8
Myosin loss is the hallmark finding of CIM.8 Cortico-
steroid use causes myosin loss, which is further triggered by 
the use of neuromuscular blockade agents used commonly 
in ICU settings. CIM can be further sub-classified as thick 
filament myopathy, catabolic myopathy, and acute necrotiz-
ing myopathy of intensive care.9 See table 2 for more details.
Elevated muscle enzyme (CK) is observed in necrotiz-
ing sub types and in other two subtypes it is either normal 
or only occasionally elevated.9 Electro diagnostic studies 
play an essential role in the diagnosis of CIM with nerve 
conduction studies exhibiting low amplitude or even absent 
motor responses, whereas sensory responses are preserved. 
Needle EMG studies show short duration, polyphasic, and 
low amplitude motor unit action potentials. EMG at rest is 
positive for fibrillation potentials/ Positive sharp waves.3
Muscle Biopsy shows muscle fiber necrosis, atrophy, 
and regeneration, mostly affecting type II fibers, in the ab-
sence of any inflammatory marker. Selective loss of thick 
filament (myosin) in the absence of thin filament (actin) is 
the hallmark.2,5,9 
Management is usually conservative. Discontinuation 
of steroids and neuromuscular blockade agents is recom-
mended. There is growing evidence in support of using in-
tensive insulin therapy for reducing the incidence of both 
Table 2: Subtypes of critical illness myopathy encountered in the intensive care unit
SUBTYPES THICK FILAMENT 
MYOPATHY
CATABOLIC
MYOPATHY 
NECROTIZING MYOPATHY OF 
INTENSIVE CARE
UNDERLYING CAUSES Corticosteroid use,
NM blockade agents, severe 
asthma exacerbation
Interleukin-1 and TNF 
induced damage seen in 
respiratory failure, shock, 
sepsis
Overwhelming infections, toxic shock
CIM and CIP.3 Although target blood glucose is to reach 
normal fasting levels with insulin infusion, an optimal dose 
remains controversial as intermediate blood glucose levels 
are safer as shown in a multi-center randomized trial.3
Prognosis usually depends upon the severity of illness.3,5
Neuromuscular Blockade
The disturbance in the neuromuscular transmission 
secondary to the use of neuromuscular blocking agents has 
been increased in recent years.1 Competitive non-depo-
larizing neuromuscular blocking agents (NMB’s) such as 
pancuronium, vecuronium, and newer benzylisoquinoline 
NMB’s such as atracurium, cisatracurium are used exten-
sively in ICU settings to aid in mechanical ventilation.1,10 
Concomitant antibiotic (aminoglycoside) and polypeptide 
antibiotics increases this block. Prolonged neuromuscular 
blockade by drugs, electrolyte disturbances, and metabolic 
acidosis acts synergistically with sepsis and SIRS in the 
pathogenesis of CIM and CIP.1,5,10-11 Slow repetitive stimula-
tion demonstrates an abnormal decrease in the compound 
muscle action potential. Careful evaluation of the con-
comitant drugs must be checked in case of any unexplained 
weakness.1
Established treatment of ICU related weakness is not 
available. The one successful intervention studied so far is 
intense insulin therapy that targets blood glucose of 80-110 
mg/dL. This intervention reduced electro physiologically 
diagnosed polyneuropathy by 49% in patients in the inten-
sive care for 7 days. In some series of patients IVIG is re-
ported to be beneficial although further studies are needed. 
Also, preventing the factors that could trigger weakness 
from certain antibiotics like aminoglycosides must be em-
ployed.11,19
Hopkins syndrome (Post-asthmatic amyotrophy)
Although rare, Hopkins syndrome (post-asthmatic 
amyotrophy) is poliomyelitis like illness, which presents 
acutely following an asthmatic attack, mostly in the pedi-
atric age group.12-14 It is an anterior horn cell disorder that 
presents as an acute flaccid paralysis of the limbs post 
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asthma attack classically.12-13 The sensation of touch and 
pain, bowel, and bladder sphincter functions preserved.13 
It could pose a diagnostic challenge to the neurologists if 
asthma were not diagnosed previously in the patient.12 The 
pathogenesis of the disease, elucidated by the combination 
of viral infection and immunocompromise in the patient, 
which aids the viral invasion into the anterior horn cell.13-14 
Immunoglobulin (IVIG) and pulse therapy with corticoste-
roids are the mainstays of therapy.13-14 Approach to muscu-
lar weakness in the ICU is depicted in figure 2.
2. Weakness Due to Preexisting Euromuscular Disorders
Spinal cord disorders. Motor weakness due to spinal cord 
disorders can be further classified into compressive and 
non-compressive myelopathy. Compressive myelopathy 
causing quadriparesis can be due to degenerative changes, 
trauma, tumor infiltration, abscess formation secondary to 
an infection, and syringomyelia.15
The most common cause of non-compressive myelop-
athy is transverse myelitis. Transverse myelitis is mostly 
idiopathic or post-infectious secondary to infection with 
viruses (CMV, Herpes, and Coxsackie) or bacteria (Myco-
plasma, Legionella). Other causes include multiple sclero-
sis, Devic’s disease, and collagen vascular disease.16-18
Transverse myelitis can be diagnosed with high clini-
cal suspicion as it presents characteristically with bilateral 
signs and symptoms, a demarcated sensory level with pro-
gression period ranging from hours to weeks. CSF shows 
characteristic pleocytosis/ or high immunoglobulin levels, 
and MRI shows increased segmental contrast enhance-
ment.18
The standard care of treatment for transverse myelitis 
includes IV corticosteroids such as methyl prednisone or 
dexamethasone, which helps in reducing spinal cord swell-
ing and inflammation. Plasma exchange can be tried in re-
fractory cases.16
Anterior Horn Cell Disorders
Amongst anterior horn cell disorders, Amyotrophic 
lateral sclerosis (ALS) is the well-known culprit causing re-
spiratory weakness, and in 10% as presenting compliant19-20 
due to primary phrenic motor neuron involvement. The 
most common cause of ICU admission in these patients is 
acute decompensation secondary to respiratory distress 
precipitated by an infection.20 
ALS presents with characteristic simultaneous upper 
and lower motor neuron involvement. The most common 
presenting symptoms include weakness, atrophy, fascicula-
                                                 High clinical suspicion 
                                   (Difficult weaning from the ventilator
                       Presence of sepsis, trauma, burns, electrolyte imbalance
                                     Medications -steroids, NMB’s)
                                                                ↓
                                      Order labs - CBC, ESR, BMP, ABG, and CK
                                                                    ↓  
                                                     (NORMAL LABS)
 
UPPER MOTOR NEURON FINDINGS             LOWER MOTOR NEURON FINDINGS 
                                                                                        
ABNORMAL MRI     ←    MRI BRAIN / SPINE                       EMG                                                  
               ↓ 
(TREAT ACC)     
                                                                                       ↙                          ↘
                                                                      NEUROPATHIC                MYOPATHIC 
                                                                        PATTERN                             PATTERN
                                                                             ↓                                            ↓
                                                                 CONSIDER NERVE/MUSCLE BIOPSY
                                                            
(CBC: complete blood count, ESR: erythrocyte sedimentation rate, BMP: basic metabolic 
panel, ABG: arterial blood gas analysis, CK: creatine kinase, ACC: accordingly, MRI: magnetic 
resonance imaging, EMG: electromyography)                
Figure 2: Approach to weakness in an ICU setting
Anterior
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tion, difficulty swallowing, slurred speech.21-22 The disease 
is usually relentlessly progressive, with death occurring in 
50% in 3 years and 80% in 5 years.22 The most common 
complication encountered in ALS patients in ICU is aspi-
ration pneumonia, secondary to respiratory failure, which 
almost always requires tracheostomy and percutaneous en-
doscopic gastrostomy(PEG) tube placement.20,23 The elec-
trophysiological study is the choice of investigation, which 
shows widespread denervation on EMG.
Other disease processes involving the anterior horn 
cell include poliomyelitis, which has been successfully 
eradicated.21 West Nile fever is also known to cause menin-
goencephalitis with acute flaccid paralysis, which usually 
presents with GBS like symptoms.21,24-25 CSF fluid shows a 
lymphocytic predominant pleocytosis.21,24-25 ELISA for IgM 
and IgG is highly sensitive and is the initial choice of investi-
gation in cases with high clinical suspicion.
Peripheral Nerve Disorders
Amongst the peripheral nerve disorders, GBS is well 
known to cause weakness in the ICU.20 GBS usually occurs 
weeks after flu-like or diarrheal illness caused by infectious 
agents such as CMV, EBV, HSV, Mycoplasma, Chlamydia, 
and Campylobacter.26-27 Weakness follows a characteristic 
fashion as rapidly progressive ascending motor and sensory 
paralysis, which later progresses to respiratory weakness 
and bulbar involvement.26 Autonomic involvement is also 
commonly seen, presenting as postural hypotension, fluc-
tuation in blood pressure, and cardiac dysrhythmias.20,26-28 
Respiratory paralysis is the most common indication for 
ICU admission.20 About 30% of patients require ventilator 
support at some time during the illness.20,26,29
The most characteristic lab finding in GBS is CSF al-
buminocytological dissociation, which usually occurs 48 
hours after the illness.27 Electro diagnostic studies show the 
Table 3: Provides a comparison between West Nile poliomyelitis and GBS.
Features West Nile poliomyelitis (16) GBS
Onset infectious post-infectious
Weakness asymmetric symmetric ascending
Sensory symptoms uncommon common
Bladder issues common uncommon
Encephalopathy common uncommon
CSF pleocytosis albuminocytological dissociation
NCS/EMG Fibrillation/positive waves Conduction blocks and temporal 
dispersion
slowing of nerve conduction velocity in addition to conduc-
tion block and temporal dispersion.27
Management of GBS in ICU settings is governed by 
two parameters, i.e., vital capacity, and ABG. Intubation is 
recommended if VC <12-15 ml/kg, falling VC, and in pa-
tients with retained secretions.29 The recommended treat-
ment options are IVIG or Plasma Exchange.26,29
Plasmapheresis is usually recommended in patients 
unable to ambulate, worsening forced vital capacity, bul-
bar muscle involvement, and in those requiring intubation 
and ventilation. Five sessions of Plasma exchange over 10 
-14 days is recommended with the exchange of a total of 
200ml of plasma/ kg body weight.20,29 Albumin is the ideal 
replacement solution for exchange.31 Blood pressure should 
be monitored every 30 minutes during the exchange period.
IVIG in the dose of 2g/kg divided over five consecutive 
days is the recommended treatment. IgA deficiency must be 
ruled out before starting the therapy.32 The patient must be 
monitored for the development of side effects such as head-
ache, malaise, nausea, and others. Combination therapies of 
IVIG and Plasma exchange are not recommended and have 
no added benefits over individual treatment.20,30,36 Steroids 
are not helpful in the treatment of GBS in ICU patients.
Neuromuscular Junction Disorders 
The most common myasthenic syndrome encountered 
in ICU includes myasthenia gravis (MG).33 The underly-
ing defect in Myasthenia gravis is the decreased number of 
available acetylcholine receptors (AChRs) at neuromuscu-
lar junction secondary to antibody-mediated immune de-
struction, thus compromising the neuromuscular conduc-
tion and presenting as the motor weakness.34 The distribu-
tion of muscle weakness has a characteristic fashion involv-
ing extraocular muscles, facial, bulbar, and later respiratory 
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involvement, and it usually presents as diplopia, dysphagia, 
difficulty in swallowing, and dysarthric speech.29,33-34 In al-
most 85% of patients, the weakness becomes generalized, 
affecting the limb muscles.35
Myasthenic crisis is the most common reason for ICU 
admission in patients with MG. Myasthenia crisis is asso-
ciated with respiratory compromise, presenting as respira-
tory muscle insufficiency and inability to handle excessive 
oral and respiratory secretions that require intubation and 
mechanical ventilation.34,36-37
In the setting of clinical worsening of myasthenia 
prompts excessive dosage of cholinesterase inhibitors, 
which increases the risk of cholinergic crisis. It is rare to see 
cholinergic crisis without concomitant myasthenia crisis. 
Cholinergic crisis is characterized by excessive secretions, 
diaphoresis, bradycardia, urinary urgency, bronchospasm, 
cramps, and weakness secondary to the peak of nicotinic 
and muscarinic toxicity. It typically occurs 2 hours after the 
last dose, and treated with atropine, pralidoxime, and/or 
glycopyrrolate.29
The most common precipitants of the myasthenic crisis 
include intercurrent infections, aspiration, sepsis, surgical 
procedure, medications, and pregnancy.38 About 30-70% of 
seronegative myasthenic patients may have antibody direct-
ed against Muscle-specific tyrosine kinase (MUSK), such 
patients tend to have severe disease and high frequency of 
respiratory crisis compared to AChR positive patients.39-40
A vital capacity less than 1 liter or (<20-25 ml/kg) or a 
negative inspiratory factor (NIF) <20 cm of H2O indicates 
significant respiratory weakness; both measurements com-
monly used to define a myasthenic crisis.29, 33-34
Around two-third to 90% of the patients with a crisis 
require intubation and mechanical ventilation and ICU 
management of the complications. Sepsis is the most com-
mon complication encountered in patients with the crisis in 
ICU settings.29
IVIG and Plasma exchange is the mainstay of treat-
ment in crisis patients.36 A typical course of IVIG is 2g/kg 
body weight daily for five days19; Five rounds of plasma ex-
change every other day for ten days is standardized therapy. 
IVIG is generally administered to total dose off 1g/Kg. most 
common side effects secondary to infusion are headache, 
nausea and fever. Renal failure and myocardial infarction 
form the hypercoagulability and aseptic meningitis is also 
reported.29
The use of 5 days pulse therapy with high dose intrave-
nous methylprednisolone reported to improve symptoms in 
the severe myasthenia with fewer side effects.40 
Botulism and tick paralysis are amongst the other neu-
romuscular junction disorders encountered in ICU. More 
than 110 cases are reported per year in the United States.41 
Botulism presents with flaccid paralysis, areflexia, and au-
tonomic disturbances. Early diagnosis is imperative as early 
antitoxin therapy is associated with a decreased hospital 
stay, morbidity, and mortality.42 Mechanical ventilation is 
the mainstay of treatment. Tick paralysis is associated with 
areflexia, ascending motor paralysis, and preserved sensa-
tions.43-44 A careful search for the ticks and their removal 
aids in the rapid resolution of symptoms.43-44
Muscle Disorders
Inflammatory myopathies commonly encountered in 
the ICU are dermatomyositis and polymyositis. Both pres-
ent with proximal muscle weakness and pain.45 Derma-
tomyositis has characteristic skin lesions such as purplish 
periorbital (heliotrope) rash, which spreads to back and 
neck as shawl sign and Gottron’s sign presenting as a rash 
over knuckles.45-46 Dermatomyositis is also more commonly 
associated with malignancies.46
The initial investigation for diagnosis involves CK lev-
els, definitive diagnosis made by muscle biopsy, and H&E 
stain. Steroids are the mainstay of treatment for inflamma-
tory myopathies.45-46
Electrolytes Disturbances
Hypokalemia is the main culprit associated with weak-
ness due to electrolyte disturbances in ICU patients.47 Low 
magnesium is associated with increased mortality by 2 to 3 
fold in the ICU patients. IV Magnesium as slow infusions 
of magnesium sulfate is the preferred in the ICU in cases of 
hypomagnesemia.47
Hypokalemic periodic paralysis presents with a recur-
rent weakness that can later progress to respiratory fail-
ure.48 Patients with hypokalemia <3.5 mEq/l respond well 
to oral or IV potassium replacement. In refractory cases, 
hypophosphatemia should be suspected.49
Conclusion
Multiple predisposing factors are involved in the devel-
opment of neuromuscular weakness in a critically ill patient 
in ICU. It could be due to a preexisting neuromuscular dis-
ease, which got exacerbated in critical illness or the com-
plication of the critical illness itself. A thorough history and 
physical examination are of paramount importance, and 
should not be omitted even though the majority of patients 
are unresponsive, confused, or sedated. Particular impor-
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tance should be given to the clues, such as the use of offend-
ing medications, underlying infections, history, and course 
of presenting illness, which help significantly in delineat-
ing the underlying disease process. Nevertheless, extensive 
imaging studies, biopsies, electrodiagnostic studies are re-
quired to reach the diagnosis in the majority of critically 
ill patients. A comprehensive investigation protocol must 
strictly adhere to all cases of weakness in ICU settings. 
The spectrum of neuromuscular disease encountered 
in ICUs today has rapidly evolved over the last decades. 
Nowadays, weakness due to CIM and CIP presents twice to 
thrice more commonly than due to primary neuromuscular 
disorders. 
Early diagnosis and prompt treatment are necessary 
not only to reduce morbidity and mortality in critically ill pa-
tients but also to reduce skyrocketing health care expenses.
Correspondence: Raghav Govindarajan, MD.
govindarajanr@health.missouri.edu
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